hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-27. Anything still debated is marked as such rather than presented as settled.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDAC or EDCI) is a water-soluble carbodiimide usually handled as the hydrochloride, which is a white solid. It is typically employed in the 4.0-6.0 pH range. It is generally used as a carboxyl activating agent for the coupling of primary amines to yield amide bonds. While other carbodiimides like dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC) are also employed for this purpose, EDC has the advantage that the urea byproduct formed (often challenging to remove in the case of DCC or DIC) can be washed away from the amide product using dilute acid. Additionally, EDC can also be used to activate phosphate groups in order to form phosphomonoesters and phosphodiesters. Common uses for this carbodiimide include peptide synthesis, protein crosslinking to nucleic acids, but also in the preparation of immunoconjugates. EDC is often used in combination with N-hydroxysuccinimide (NHS) for the immobilisation of large biomolecules. Recent work has also used EDC to assess the structure state of uracil nucleobases in RNA.
Lead (82Pb) has four observationally stable isotopes: 204Pb, 206Pb, 207Pb, 208Pb. Lead-204 is entirely a primordial nuclide and is not a radiogenic nuclide. The three isotopes lead-206, lead-207, and lead-208 represent the ends of three decay chains: the uranium series (or radium series), the actinium series, and the thorium series, respectively; a fourth decay chain, the neptunium series, terminates with the thallium isotope 205Tl. The three series terminating in lead represent the decay chain products of long-lived primordial 238U, 235U, and 232Th. Each isotope also occurs, to some extent, as primordial isotopes that were made in supernovae, rather than radiogenically as daughter products. The fixed ratio of lead-204 to the primordial amounts of the other lead isotopes may be used as the baseline to estimate the extra amounts of radiogenic lead present in rocks as a result of decay from uranium and thorium. This is the basis for lead–lead dating and uranium–lead dating. The longest-lived radioisotopes, both decaying by electron capture, are 205Pb with a half-life of 17.0 million years and 202Pb with a half-life of 52,500 years. A shorter-lived naturally occurring radioisotope, 210Pb with a half-life of 22.2 years, is useful for studying the sedimentation chronology of environmental samples on time scales shorter than 100 years. The heaviest stable isotope, 208Pb, belongs to this element. (The more massive 209Bi, long considered to be stable, actually has a half-life of 2.01×1019 years.) 208Pb is also a doubly magic isotope, as it has 82 protons and 126 neutrons.
Non-diabetics' beta cells routinely and automatically manage this by continual glucose level monitoring and insulin release. All such decisions by a diabetic must be based on experience and training (i.e., at the direction of a physician, PA, or in some places a specialist diabetic educator) and, further, specifically based on the individual experience of the person. But it is not straightforward and should never be done by habit or routine. With some care however, it can be done reasonably well in clinical practice. For example, some people with diabetes require more insulin after drinking skim milk than they do after taking an equivalent amount of fat, protein, carbohydrate, and fluid in some other form. Their particular reaction to skimmed milk is different from other people with diabetes, but the same amount of whole milk is likely to cause a still different reaction even in that person. Whole milk contains considerable fat while skimmed milk has much less. It is a continual balancing act for all people with diabetes, especially for those taking insulin. People with insulin-dependent diabetes typically require some base level of insulin (basal insulin), as well as short-acting insulin to cover meals (bolus also known as mealtime or prandial insulin). Maintaining the basal rate and the bolus rate is a continuous balancing act that people with insulin-dependent diabetes must manage each day.
In October 2008, Anatoly Barankevich, the head of the Security Council of South Ossetia, said in an interview that during the war, "Firstly, they [the Georgians] had T-72 tanks, and we only have three tanks, and they are T-55, [...] We had moved them out secretly, put them near the city, and they did a good job, and then entered the city." Researcher Andrey Illarionov later commented on the remarks of Barankevich, "This means that the tanks were in the conflict zone. Near Tskhinvali, which is prohibited by the Dagomys Agreement." In November 2008, Novaya Gazeta reported that Valentin Malykh received a phone call from his son in Vladikavkaz on the early morning of August 7 and Valentin wanted to congratulate his son on his birthday. But his son said that he was being sent to the war in Tskhinvali.
=== Cure rate variation === Some of Mohs' data revealed a cure rate as low as 96%, but these were often very large tumors, previously treated by other modalities. Some authors claim that their 5-year cure rate for primary basal-cell cancer exceeded 99% while other noted more conservative cure rate of 97%. The quoted cure rate for Mohs surgery on previously treated basal-cell cancer is about 94%. Reasons for variations in the cure rate include the following.
Sources: en.wikipedia.org
=== German reunification === West German chancellor Helmut Kohl's proposal of a Ten Point Plan on 28 November 1989—a graduated progression from confederation to full federation—moved the German question from a mere platitude to actual politics almost overnight, and the storm of international criticism it provoked was the price of that shift. Gorbachev's opposition, Thatcher's criticism, and French president François Mitterrand's vacillation notwithstanding, Kohl pushed for immediate unification once Dresden crowds took up chanting his name that December; unlike their more cautious political elites, ordinary people in the neighboring countries mostly favored German self-determination. This proposal presented a special dilemma for Gorbachev, since a "divided Germany" had been central to Soviet security strategy since the Stalin era. The resulting Two-Plus-Four negotiations—originally conceived by the U.S. State Department as a "four-plus-two" framework joining the wartime Allies with the two German states, then inverted to acknowledge German sensitivities—translated the East German electorate's March 1990 mandate into an accepted international settlement. In return, Kohl accepted the Oder–Neisse line as Germany's permanent eastern frontier in exchange for keeping reparations off the table, while American pressure and West German aid persuaded Gorbachev to permit a reunified Germany to remain in NATO. Then U.S. Secretary of State James Baker assured Gorbachev on 9 February 1990 that NATO would not expand eastward.
==== EU ==== On July 27, 2025, the United States and the European Union concluded a trade agreement, providing for 15% tariffs on European exports. The deal was announced by Trump and President of the European Commission Ursula von der Leyen at Turnberry, Scotland. European states committed to $750 billion in energy purchases and $600 billion in additional investments in the United States.
=== Pharmaceuticals === GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes mellitus, and mental health. Medicines historically discovered or developed at GSK and its legacy companies and now sold as generics include amoxicillin and amoxicillin-clavulanate, ticarcillin-clavulanate, mupirocin, and ceftazidime for bacterial infections, zidovudine for HIV infection, valacyclovir for herpes virus infections, albendazole for parasitic infections, sumatriptan for migraine, lamotrigine for epilepsy, bupropion and paroxetine for major depressive disorder, cimetidine and ranitidine for gastroesophageal reflux disorder, mercaptopurine and thioguanine for the treatment of leukemia, allopurinol for gout, gepotidacin for UTIs, pyrimethamine for malaria, and the antibacterial trimethoprim. Among these, albendazole, amoxicillin, amoxicillin-clavulanate, allopurinol, mercaptopurine, mupirocin, pyrimethamine, ranitidine, thioguanine, trimethoprim, and zidovudine are on the World Health Organization's List of Essential Medicines.
Isotopomerism is analogous to constitutional isomerism or stereoisomerism of different elements in a structure. Depending on the formula and the symmetry of the structure, there might be several isotopomers of one isotopologue. For example, ethanol has the molecular formula C2H6O. Mono-deuterated ethanol, C2H5DO or C2H52HO, is an isotopologue of it. The structural formulas CH3−CH2−O−D and CH2D−CH2−O−H are two isotopomers of that isotopologue.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.